Table 2.
Phytonadione Dosing and Additional Factors Affecting International Normalized Ratio
| Characteristics |
All Patients
(n = 156) |
Patients Without a Follow-up INR (n = 10) |
Patients With a Normalized INR <1.2
(n = 66) |
Patients With INR >1.2
(n = 80) |
P value |
|---|---|---|---|---|---|
| No. (%) or Median (IQR) | |||||
| Total number of phytonadione doses | 2.0 (1–3) | 3 (2–3) | 3 (2–3) | 0.58* | |
| Phytonadione dosage: | |||||
| Initial dose, mg | 1.0 (1.0–5.0) | 2.8 (1.3–5.0) | 1.0 (1.0–5.0) | 1.0 (1.0–2.75) | 0.56* |
| Initial dose, mg/kg | 0.12 (0.05–0.26) | 0.15 (0.09–0.30) | 0.12 (0.05–0.23) | 0.13 (0.05–0.26) | 0.50* |
| Cumulative dose, mg | 3.00 (2.01–9.00) | 6.75 (3.00–10.00) | 3.00 (2.50–10.00) | 3.00 (2.00–8.50) | 0.60* |
| Cumulative dose, mg/kg | 0.27 (0.12–0.71) | 0.19 (0.12–0.57) | 0.27 (0.12–0.60) | 0.30 (0.11–0.79) | 0.47* |
| Total number of INRs collected† | – | 1 (1) | 4 (3–6) | 4 (3–7) | 0.40* |
| FFP | 83 (53.2) | 5 (50.0) | 28 (42.4) | 50 (62.5) | 0.02‡ |
| Cryoprecipitate | 20 (12.8) | 0 | 10 (15.2) | 10 (12.3) | 0.65‡ |
| FFP and cryoprecipitate | 16 (10.3) | 0 | 7 (10.6) | 9 (11.3) | 0.90§ |
FFP, fresh frozen plasma; INR, international normalized ratio
*Wilcoxon 2-sample test.
†Data presented as median (IQR).
‡Chi-square test.
§Exact chi-square test.